BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
by Zacks Equity Research
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
What's in the Cards for Aeterna (AEZS) This Earnings Season?
by Zacks Equity Research
Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up
by Zacks Equity Research
Endo's (ENDP) earnings and revenues top expectations in the fourth quarter.
Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018
by Zacks Equity Research
Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.
The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.
Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat
by Zacks Equity Research
Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.
Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.
Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) surpasses earnings and sales estimates in the fourth quarter and issues a solid outlook for 2019. Shares rise 8% in after-hours trading.
5 Affordable Breakout Stocks for Superlative Returns
by Swarup Gupta
Seeking breakout stocks is probably one of the most favored techniques among active investors.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.
Amgen Starts Phase III Enrollment for Heart Failure Drug
by Zacks Equity Research
Amgen (AMGN) and partners started enrollment for the second phase III study of omecamtiv mecarbil, which is being developed for the potential treatment of heart failure with reduced ejection fraction.
What's in Store for Vericel (VCEL) This Earnings Season?
by Zacks Equity Research
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings might suffer high expenses, partly offset by rise in revenues.
bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.
BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline
by Zacks Equity Research
BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.
BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, BioDelivery Sciences International (BDSI) closed at $4.73, marking a -0.63% move from the previous day.
Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
by Zacks Equity Research
Agios' (AGIO) label expansion filing eyes an approval of Tibsovo for newly diagnosed acute myeloid leukemia patients with an IDH1 mutation. The drug also gets a priority review tag from the FDA.
Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
by Zacks Equity Research
TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.
Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Ultragenyx (RARE) loss narrower than expected and sales beat estimates in the fourth quarter of 2018.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.
Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
by Zacks Equity Research
Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.